Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | ABL1 | P00519 | 7/20 | 0.42 |
| ▸ | HCK | P08631 | 7/20 | 0.42 |
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.42 |
| ▸ | MTOR | P42345 | 6/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.42 |
| ▸ | PRKDC | P78527 | 6/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717774 | 0.89 | PIK3CD (0.41) | CSNK1EPIK3CDPIK3CGPIK3R1SRC | |
| SCHEMBL13717931 | 0.87 | SRC (0.48) | PIK3CDPIK3CGSRCABL1HCK | |
| SCHEMBL11306 | 0.87 | SRC (0.47) | PIK3CDPIK3CGSRCABL1HCK | |
| SCHEMBL13718435 | 0.86 | MKNK1 (0.39) | CSNK1EPIK3CDPIK3CGPIK3R1EGFR | |
| SCHEMBL20093481 | 0.86 | KMO (0.46) | PIK3CDPIK3CGSRCABL1HCK | |
| SCHEMBL13717565 | 0.85 | LRRK2 (0.40) | CSNK1EPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL217790 | 0.85 | ABL1 (0.49) | PIK3CDPIK3CGSRCABL1HCK | |
| SCHEMBL22692856 | 0.81 | ERBB2 (0.50) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL13717860 | 0.80 | LRRK2 (0.51) | — | |
| SCHEMBL20093561 | 0.80 | BTK (0.47) | PIK3CDPIK3CGSRCABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| EP-4149944-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | Fochon Biosciences, Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| CN-112142745-B | Casein kinase 1 epsilon inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220251092-A1 | CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2022-08-11 | — | — | US | disclosed |
| US-20220251092-A1 | CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2022-08-11 | — | — | US | disclosed |
| US-11352359-B2 | PI3K protein kinase inhibitors | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-07 | — | — | US | disclosed |
| EP-3964512-A1 | CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| EP-3964512-A1 | CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-20210403475-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-9150579-B2 | Selective PI3K delta inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2015-10-06 | — | — | US | disclosed |
| EP-2870157-A1 | SELECTIVE PI3K DELTA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2015-05-13 | — | — | EP | disclosed |
| WO-2015001491-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2015-01-08 | — | — | WO | disclosed |
| US-20140011819-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| WO-2014006572-A1 | SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-01-09 | — | — | WO | disclosed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352359-B2 | PI3K protein kinase inhibitors | PIK3CD, PIK3R5, PIK3CB | CSNK1E 112/4885PIK3CD 1/4885PIK3CG 6/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | CSNK1E 110/4885PIK3CD 47/4885PIK3CG 77/4885 |
| US-20140011819-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | CSNK1E 78/4885PIK3CD 1/4885PIK3CG 7/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | CSNK1E 110/4885PIK3CD 47/4885PIK3CG 77/4885 |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, PIK3CB | CSNK1E 174/4885PIK3CD 4/4885PIK3CG 5/4885 |
| US-20210403475-A1 | NOVEL SELECTIVE PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3C2B | CSNK1E 78/4885PIK3CD 1/4885PIK3CG 7/4885 |
| US-20220251092-A1 | CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1E 1/4885PIK3CD 439/4885PIK3CG 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.